期刊文献+

阿尔茨海默病睡眠障碍研究进展 被引量:5

Research progress of the sleep disorder in Alzheimer's disease
原文传递
导出
摘要 睡眠障碍是阿尔茨海默病(AD)患者常见的临床症状而血清载脂蛋白E4及外界因素等可能是AD睡眠障碍的危险因素。AD睡眠障碍的特点包括片段化睡眠,夜间睡眠时间减少,日间思睡,严重的甚至表现为昼夜节律颠倒以及睡眠呼吸障碍等。AD睡眠障碍治疗包括非药物治疗,以及包括乙酰胆碱酯酶抑制剂、褪黑素、镇静催眠药、抗精神病药物等在内的药物治疗。本文主要综述AD睡眠障碍的特点及治疗进展。 The sleep disorder is a common symptom in Alzheimer's disease(AD) patients, which is characterized as the nocturnal sleep fragmentation, nocturnal sleep duration decreasing, diurnal napping, the even inversion of sleep-wake cycle and breathing disorder. Generally, the apolipoprotein epsilon E4 and environmental factors are responsible for the sleep disturbance in AD patients. The treatment of sleep disorder for the elderly AD patients is consisted of non-drugs therapy and drug therapy including cholinesterase inhibitors, melatonin, hypnotics and antipsychotics. This article reviews the characteristics and treatment progress of sleep disorder in AD.
出处 《世界临床药物》 CAS 2017年第2期73-77,共5页 World Clinical Drug
基金 国家自然科学基金(编号:30900473 81371459) 国家科技部重大专项(编号:2011ZXJ09202-015) 上海市自然科学基金(编号:15ZR1414600) 国家科技支撑计划项目(编号:2015BAI13B01)
关键词 阿尔茨海默病(AD) 睡眠障碍 临床治疗 Alzheimer's disease(AD) sleep disorder clinical treatment
  • 相关文献

参考文献3

二级参考文献71

  • 1黄艳,董志.氧化应激和阿尔茨海默病[J].中国临床药理学与治疗学,2005,10(5):485-488. 被引量:11
  • 2官志忠,齐晓岚.氧化应激和神经递质受体在阿尔茨海默病发病机制中的作用[J].贵阳医学院学报,2006,31(1):64-69. 被引量:2
  • 3于德红,魏朝良,包永明,安利佳.阿尔茨海默病与氧化应激[J].生物医学工程学杂志,2006,23(5):1142-1144. 被引量:10
  • 4PRATICO D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows[ J]. Ann NY Acad Sci, 2008, 1147:70 -78.
  • 5EMERIT J, EDEAS M, BRICAIRE F. Neurodegenerative diseases and oxidative stress [J] .Biomed Pharmacother, 2004, 58 (1): 39-46.
  • 6CASADO A, ENCARNACION LOPEZ-FERNANDEZ M, CONCEPCION CASADO M, et al. Lipid peroxidation and antioxidan enzyme activities in vascular and Alzheimer dementias [ J ]. Neu rochem Res, 2008, 33(3) : 450 -458.
  • 7GREILBERGER J, KOIDL C, GRE1LBERGER M, et al. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease[ J ]. Free Radio Res, 2008, 42 (7) : 633 - 638.
  • 8LOVELL MA, MARKESBERY WR. Oxidatively modified RNA in mild cognitive impairment [ J ]. Neurobiol Dis, 2008, 29 ( 2 ) : 169 - 175.
  • 9DUKIC-STEFANOVIC S, SCHINZEE R, R1EDERER P, et al. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementiadrugs? [J]. Biogerontology, 2001, 2(1): 19 -34.
  • 10JEYNES B, PROVIAS J. Evidence for altered LRP/RAGE expression in Alzheiiner lesion pathogenesis [ J 1. Curr Alzheimer Res, 2008, 5(5) : 432 -437.

共引文献10

同被引文献34

引证文献5

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部